Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
复制标题
对残留或有反应的复发性卵巢癌患者进行高剂量静脉注射阿霉素、依托泊苷和环磷酰胺联合自体干细胞支持的 II 期试验。
DOI：
10.1038/sj.bmt.1703243
复制
发表时间：
2001
期刊：
影响因子：
--
通讯作者：
Yen,Y
中科院分区：
文献类型：
--
作者：
Morgan,RJ;Doroshow,JH;Leong,L;Schriber,J;Shibata,S;Forman,S;Hamasaki,V;Margolin,K;Somlo,G;Alvarnas,J;McNamara,M;Longmate,J;Raschko,J;Chow,W;Vasilev,S;McGonigle,K;Yen,Y
本研究的目的是评估高剂量化疗对有效残留或复发卵巢癌患者的毒性、无进展生存率和总生存率。27名患者接受了治疗。多柔比星，165 mg/m2，持续96 h（第-12天至第-8天），依托泊苷700 mg/m2，每天× 3（第-6天至第-4天），环磷酰胺4.2 g/m2，第-3天，随后是干细胞和粒细胞集落刺激因子。粒细胞计数< 500/μl的中位天数为14天（10-42天），血小板计数<20000/μl的中位天数为13天（2-80天）。输注红细胞和血小板的中位数量分别为15（5-16）和14（4-103）。所有患者的毒性包括需要麻醉镇痛的粘膜炎。在4例患者中观察到射血分数无症状降低至< 50%。未观察到临床充血性心力衰竭。观察到1例因败血症死亡。中位无进展生存期为7.5个月（1.0-56个月）; 5例患者仍然存活，其中2例在移植后19.5和24.5个月保持无进展。中位总生存期为14.0个月（1-68个月）。我们的结论是，高剂量的蒽环类药物可以安全地管理卵巢癌患者。在我们的人群中观察到的短的总体和无进展生存期表明这种组合不是最佳的。骨髓移植（2001）28，859-863。
This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m 2 over 96 h (days− 12 to− 8), etoposide 700 mg/m 2 every day× 3 (days− 6 to− 4), and cyclophosphamide 4.2 g/m 2 on d− 3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count< 500/μl was 14 (range 10–42) and platelets< 20 000/μl was 13 (range 2–80). Median numbers of red cell and platelet transfusions were 15 (5–16) and 14 (4–103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values< 50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0–56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1–68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal. Bone Marrow Transplantation (2001) 28, 859–863.